Neuromodulation versus medication for overactive bladder: The case for early intervention

Current Urology Reports

Volumn 10, Issue 5, 2009, Pages 342-346

  Peters, Kenneth M ^a   Burks, Frank N ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; DARIFENACIN; FESOTERODINE; OXYBUTYNIN; PLACEBO; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

BLURRED VISION; CLINICAL TRIAL; COGNITIVE DEFECT; CONSTIPATION; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INJURY; INTERMETHOD COMPARISON; NEUROMODULATION; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT SELECTION; POSTVOID RESIDUAL URINE VOLUME; RANDOMIZED CONTROLLED TRIAL; REVIEW; SIDE EFFECT; TIBIAL NERVE; TREATMENT OUTCOME; URINARY TRACT INFECTION; XEROSTOMIA;

ELECTRIC STIMULATION THERAPY; HUMANS; LUMBOSACRAL PLEXUS; NEUROTRANSMITTER AGENTS; TIME FACTORS; URINARY BLADDER, OVERACTIVE;

EID: 69249189809     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-009-0054-3     Document Type: Review

References (43)

1. A.J. Wein E.S. Rovner 2002 Definition and epidemiology of overactive bladder Urology 60 5Suppl1 7 12
2. S. Tyagi C.A. Thomas Y. Hayashi M.B. Chancellor 2006 The overactive bladder: epidemiology and morbidity Urol Clin North Am 33 433 438
3. K.S. Coyne C. Payne S.K. Bhattacharyya, et al. 2004 The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: results from a national community survey Value Health 7 455 463
4. T. Hu T.H. Wagner J.D. Bentkover, et al. 2003 Estimated economic costs of overactive bladder in the United States Urology 61 1123 1128
5. D.E. Irwin I. Milsom Z. Kopp, et al. 2005 Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries BJU Int 97 96 100
6. B.H. Zorn H. Montgomery K. Pieper, et al. 1999 Urinary incontinence and depression J Urol 102 82 84
7. S.R. Aboseif D.H. Kim J.M. Rieder, et al. 2007 Sacral neuromodulation: cost considerations and clinical benefit Urology 70 1069 1074
8. Y. Yarker K.L. Goa A. Fitton 1995 Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability Drugs Aging 6 243 262
9. P. Abrams K.E. Andersson 2007 Muscarinic receptor antagonists for overactive bladder BJU Int 100 987 1006
10. A.C. Diokno R.A. Appell P.K. Sand, et al. 2003 Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial Mayo Clin Proc 78 687 695
11. M. Brazzelli A. Alison Murray C. Fraser 2006 Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review J Urol 175 835 841
12. C.J. Kelleher L.D. Cardozo V. Khuller S. Salvatore 1997 A medium-term analysis of the subjective efficacy of treatment for women with detrusor instability and low bladder compliance Br J Obstet Gynaecol 104 988 993
13. Y.F. Yu M.B. Nichols A.P. Yu J. Ahn 2005 Persistence and adherence of medications for chronic overactive bladder/urinary incontinence in the California Medicaid population Value Health 8 495 505
14. M. Gopal K. Haynes S.L. Bellamy L.A. Arya 2008 Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms Obstet Gynecol 112 1311 1318
15. P.E. van Kerrebroeck A.C. van Voskuilen J. Heesakkers, et al. 2007 Results of sacral neuromodulation therapy for urinary voiding dysfunction: outcomes of a prospective, worldwide clinical study J Urol 178 2029 2034
16. B.F. Blok J. Groen J.L. Bosch, et al. 2006 Different brain effects during chronic and acute sacral neuromodulation in urge incontinent patients with implanted neurostimulators BJU Int 98 1238 1243
17. S. Malaguti M. Spinelli G. Giardiello, et al. 2003 Neurophysiological evidence may predict the outcome of sacral neuromodulation J Urol 170 2323 2326
18. R.T. Foster Sr E. Anoia G.D. Webster C.L. Amundsen 2007 In patients undergoing neuromodulation for intractable urge incontinence, a reduction in 24 hour pad weight after the initial test stimulation best predicts long term patient satisfaction Neurourol Urodyn 26 213 217
19. C.L. Amundsen A.A. Romero M.J. Jamison G.D. Webster 2005 Sacral neuromodulation for intractable urge incontinence: are there factors associated with cure? Urology 66 746 750
20. P.M. Groenendijk A.A. Lycklama à Nyeholt J. Heesakkers, et al. 2007 Urodynamic evaluation of sacral neuromodulation for urge urinary incontinence BJU Int 101 325 329
21. W.D. Tissot A.C. Diokno K.M. Peters 2004 A referral center's experience with transitional cell carcinoma misdiagnosed as interstitial cystitis J Urol 172 478 480
22. M.B. Chancellor F. de Miguel 2007 Treatment of overactive bladder: selective use of anticholinergic agents with low drug-drug interaction potential Geriatrics 62 15 24
23. C.L. Amundsen G.D. Webster 2002 Sacral neuromodulation in an older, urge incontinent population Am J Obstet Gynecol 187 1462 1465
24. D.M. Gaynor-Krupnick N.T. Dwyer H. Rittenmeyer K.J. Kreder 2006 Evaluation and management of malfunctioning sacral neuromodulator Urology 67 246 249
25. S.E. Sutherland A. Lavers A. Carlson, et al. 2007 Sacral nerve stimulation for voiding dysfunction: one institution's 11 year experience Neurourol Urodyn 26 19 28
26. W.M. White J.D. Mobley R. Doggweiler, et al. 2009 Incidence and predictors of complications with sacral neuromodulation Urology 73 731 735
27. M.S. Elkelini M.M. Hassouna 2006 Safety of MRI at 1.5 Tesla in patients with implanted sacral nerve neurostimulator Euro Urol 50 311 316
28. M.R. Cooperberg M.L. Stoller 2005 Percutaneous neuromodulation Urol Clin North Am 32 71 78
29. F. Govier S. Litwiller V. Nitti, et al. 2001 Percutaneous afferent modulation for the refractory over active bladder: results of a multicenter study J Urol 165 1193 1198
30. M.R. van Balken V. Vandoninck K. Gisolf, et al. 2001 Posterior tibial nerve stimulation as neuromodulatory treatment of lower urinary tract dysfunction J Urol 166 914 918
31. H.C. Klingler A. Pycha J. Schmidbauer M. Marberger 2000 Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study Urology 56 766 771
32. Peters KM, MacDiarmid SA, Wooldridge LS, et al.: Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy (OrBIT) trial. J Urol 2009 (in press).
33. K.J. Propert C.K. Payne J.W. Kusek L.M. Nyberg 2002 Pitfalls in the design of clinical trials for interstitial cystitis Urology 60 742 748
34. K.M. Peters D.J. Carrico F.B. Burks 2009 Validation of a sham for percutaneous tibial nerve stimulation Neurourol Urodyn 28 58 61
35. H. Petit E. Wiart E. Gaujard, et al. 1998 Botulinum A toxin treatment of detrusor-sphincter dyssynergia in spinal cord disease Spinal Cord 36 91 94
36. C.P. Smith M.E. Franks B.K. McNeil, et al. 2003 Effect of botulinum toxin A on the autonomic nervous system of the rat lower urinary tract J Urol 169 1896 1900
37. Y. Wakabayashi Y. Kojima Y. Makiura, et al. 2005 Acetylcholinesterase positive axons in the mucosa of urinary bladder in cats: retrograde tracing and degeneration studies Histol Histopathol 10 523 530
38. M. Khera G.T. Somogyi S. Kiss, et al. 2004 Botulinum toxin A inhibits ATP release from bladder urothelium after chronic spinal cord injury Neurochem Int 45 987 993
39. A. Sahai M.S. Khan P. Dasgupta 2007 Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double blind, placebo controlled trial J Urol 177 2231 2236
40. D.M. Schmid P. Sauermann M. Werner, et al. 2006 Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics J Urol 176 177 185
41. B. Schurch M. de Seze P. Denys, et al. 2005 Botulinum toxin type A is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174 196 200
42. V. Kalsi R.B. Popat A. Apostolidis, et al. 2006 Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK centre Eur Urol 49 519 527
43. J.M. Wu N.Y. Siddiqui C.L. Amundsen, et al. 2009 Cost-effectiveness of botulinum toxin A versus anticholinergic medications for idiopathic urge incontinence J Urol 181 2181 2186